Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family
about
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisA restraint molecular dynamics and simulated annealing approach for protein homology modeling utilizing mean anglesInsights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligandsStructural basis for the activation of PPARgamma by oxidized fatty acidsAdaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structuresThe nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolitesAmorfrutins are potent antidiabetic dietary natural productsDesign novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approachScaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptorsMonitoring Solution Structures of Peroxisome Proliferator-Activated Receptor β/δ upon Ligand BindingTesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker ratsDiscovery of ligands for Nurr1 by combined use of NMR screening with different isotopic and spin-labeling strategies.Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution.Virtual Screening as a Technique for PPAR Modulator Discovery.Design, sythesis and evaluation of a series of 3- or 4-alkoxy substituted phenoxy derivatives as PPARs agonists.PPARalpha: energy combustion, hypolipidemia, inflammation and cancerLeukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist.Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazoneThe endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humansMolecular recognition of agonist and antagonist for peroxisome proliferator-activated receptor-α studied by molecular dynamics simulations.Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors.Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain.Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discoveryInvestigational PPAR-gamma agonists for the treatment of Type 2 diabetes.Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Structure and activation of rhodopsin.Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARalpha).Caenorhabditis elegans nuclear receptors: insights into life traits.Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.Interference of pollutants with PPARs: endocrine disruption meets metabolism.Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.Activation of PPARδ: from computer modelling to biological effects.A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects.AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.Arjunolic Acid, a Peroxisome Proliferator-Activated Receptor Alpha Agonist Regresses Cardiac Fibrosis by Inhibiting Non-canonical TGF-β Signaling.Peroxisome proliferator-activated receptor α ligands and modulators from dietary compounds: Types, screening methods and functions.
P2860
Q24541529-47480DF4-87E0-4BA0-A959-29F0CFCB4286Q24804455-B41B8FDE-2B66-4148-99D4-41226CC137EBQ27644330-C86BAA55-F6C5-4065-99AC-A545C9C6BEA6Q27653525-350FE005-FCE4-4377-BBDC-5AB2E530B89DQ27656610-C0C067E6-B905-4165-A847-69D4D4BA9718Q27664075-788B61F9-622E-466B-8F89-78AF18D33E19Q27678567-7A570FF7-6993-466B-AB8C-2A3811BF52B4Q28484141-2FC82D21-F6C5-4E64-93F6-B5E997A7744BQ28484657-E047E074-EC78-4BFA-AACF-F7D44D68BB86Q28550888-61C5CD99-9804-4246-AEA5-F517AE2413F0Q28572510-BCEE7972-C3A9-40E2-A4C3-BF7A0E81FD2AQ33282238-1A9B67BF-6A84-4055-8751-EFCECB60F970Q33304896-DAAAB923-AB4B-439C-A4C6-ACDB686A3C5BQ33502225-425A9E65-F7CF-4179-8440-8DFF7548B352Q33591341-DCCC728A-5FC5-482B-963E-D9BF7EBB4884Q33805104-825F7BC0-CBA0-4E6E-90E7-F6A24FAF727CQ33991108-3898E22B-9624-45A3-844A-057E779B286DQ34511474-AFF5A030-3676-4B56-B6FA-A3391635F177Q34623928-DEE6FAB9-1B02-4E4D-8F95-BA1D51F2CCAAQ35019725-4C3066C1-D6E4-46C6-B86F-FE2E5FE899F0Q35170491-868102AA-38F7-4B9A-A991-D885A19046CCQ35207615-22EA2805-C900-42B0-A53D-74646A9ED59BQ35562822-E361FB69-225A-4AA8-A258-C3223E61BD30Q35865401-F601452E-7912-4FE1-BDA9-0CDBEB3E1BD3Q36218321-63B6900C-D369-4192-BE1E-5E31C9BAC7FEQ36497819-6E5D7139-AA05-4FBB-B09E-5BB3115EA07CQ36512559-B7017636-C235-49E4-A594-5BE2A1B289C6Q36580568-AD0DA6C4-17EE-4448-A15D-3EAD279844B9Q36914861-B983309E-26DD-4EAE-9822-B876C4DA0EC7Q36995946-4BC6638B-B228-49DB-9C8E-93F618BCCEEAQ37136034-5749E43F-E5DA-4A86-A0B7-10E8AC43832CQ37197332-E96273AA-B554-4511-BBC3-C3277FBE9DE4Q37304485-4B9DAC10-C3D3-4096-8B76-D1635BA7FE63Q37349822-D1923ECC-2662-4373-91DF-A438FFFBF894Q38066606-3B0641EB-3F21-4E75-B9BB-204CB2C4D0CEQ38254275-97E85A30-6116-45C3-98AB-D588AD0C8D52Q38338794-60BFDE03-0806-4982-8F72-E8214031D856Q38361567-87F74931-B463-413B-AF0F-064C077526F0Q38618013-048252E4-8C20-424E-B8B9-A93D63675768Q39013200-1B0A5EA3-6002-45F9-8BA1-1D6F29F3050E
P2860
Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Structure of the PPARalpha and ...... activation in the PPAR family
@ast
Structure of the PPARalpha and ...... activation in the PPAR family
@en
Structure of the PPARalpha and ...... activation in the PPAR family
@nl
type
label
Structure of the PPARalpha and ...... activation in the PPAR family
@ast
Structure of the PPARalpha and ...... activation in the PPAR family
@en
Structure of the PPARalpha and ...... activation in the PPAR family
@nl
prefLabel
Structure of the PPARalpha and ...... activation in the PPAR family
@ast
Structure of the PPARalpha and ...... activation in the PPAR family
@en
Structure of the PPARalpha and ...... activation in the PPAR family
@nl
P2093
P3181
P1433
P1476
Structure of the PPARalpha and ...... activation in the PPAR family
@en
P2093
E L Lindstedt
J F Petersen
U Karlsson
P304
P3181
P356
10.1016/S0969-2126(01)00634-7
P577
2001-08-01T00:00:00Z